Shares plummet as St Jude sounds warning of Q3 earnings shortfall
This article was originally published in Clinica
St Jude Medical’s share price on the NYSE dropped by around 14% after it lowered profit targets as a result of weaker-than-expected third-quarter sales across the majority of its product categories. On October 6 – the day that St Jude announced its preliminary Q3 results – shares opened at $32.70 each, a significant drop from $38.24, at which shares closed the previous day.
You may also be interested in...
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals